David A. Siegel Denali Therapeutics Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 27,600 shares of DNLI stock, worth $476,100. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,600

Previous 35,300 21.81%

Holding current value

$476,100

Previous $480,000 19.58%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$11.47 - $16.65 $88,319 - $128,204	-7,700 Reduced 21.81%	27,600 $386,000
Q1 2025 May 15, 2025	BUY	$13.6 - $23.59 $274,720 - $476,518	20,200 Added 133.77%	35,300 $480,000
Q4 2024 Feb 14, 2025	BUY	$20.24 - $31.58 $305,624 - $476,858	15,100 New	15,100 $307,000
Q1 2024 May 15, 2024	BUY	$15.83 - $23.35 $346,677 - $511,365	21,900 New	21,900 $449,000
Q2 2023 Aug 14, 2023	SELL	$23.37 - $32.96 $2.14 Million - $3.02 Million	-91,500 Reduced 77.61%	26,400 $779,000
Q1 2023 May 15, 2023	SELL	$21.91 - $32.67 $742,749 - $1.11 Million	-33,900 Reduced 22.33%	117,900 $2.72 Million
Q4 2022 Feb 14, 2023	SELL	$26.28 - $33.92 $840,960 - $1.09 Million	-32,000 Reduced 17.41%	151,800 $4.22 Million
Q3 2022 Nov 14, 2022	BUY	$25.97 - $38.53 $605,101 - $897,749	23,300 Added 14.52%	183,800 $5.64 Million
Q2 2022 Aug 15, 2022	SELL	$20.88 - $35.19 $244,296 - $411,723	-11,700 Reduced 6.79%	160,500 $4.72 Million
Q1 2022 May 16, 2022	SELL	$29.0 - $47.27 $2.82 Million - $4.6 Million	-97,400 Reduced 36.13%	172,200 $5.54 Million
Q4 2021 Feb 14, 2022	SELL	$42.59 - $55.02 $6.45 Million - $8.34 Million	-151,500 Reduced 35.98%	269,600 $12 Million
Q3 2021 Nov 15, 2021	SELL	$48.48 - $78.23 $2.08 Million - $3.36 Million	-43,000 Reduced 9.27%	421,100 $21.2 Million
Q2 2021 Aug 16, 2021	BUY	$50.3 - $78.44 $643,840 - $1 Million	12,800 Added 2.84%	464,100 $36.4 Million
Q1 2021 May 17, 2021	BUY	$53.8 - $81.53 $10.2 Million - $15.5 Million	190,200 Added 72.85%	451,300 $25.8 Million
Q4 2020 Feb 16, 2021	BUY	$36.89 - $93.56 $7.4 Million - $18.8 Million	200,700 Added 332.28%	261,100 $21.9 Million
Q3 2020 Nov 16, 2020	BUY	$23.13 - $38.84 $1.11 Million - $1.87 Million	48,200 Added 395.08%	60,400 $2.16 Million
Q2 2020 Aug 14, 2020	BUY	$16.01 - $28.82 $195,322 - $351,604	12,200 New	12,200 $295,000

Others Institutions Holding DNLI

# of Institutions

248

Shares Held

135M

Call Options Held

148K

Put Options Held

15.4K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.31B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account